- Conditions
- Coronary Artery Disease
- Interventions
- Lumason
- Drug
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 8
- States / cities
- Santa Ana, California • Wilmington, Delaware • Homestead, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 26
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hydrocephalus in Infants, Hydrocephalus Acquired
- Interventions
- Sulfur Hexafluoride Lipid Type A Microspheres 25 mg Injection Powder for Suspension [LUMASON]
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Minute to 18 Months
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Appendicitis
- Interventions
- Sulfur hexafluoride lipid-type A microspheres
- Drug
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Von-Hippel Lindau, Kidney Disease, Chronic
- Interventions
- Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 16 Years to 99 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Urinary Tract Infection, Vesicoureteral Reflux
- Interventions
- Sulfur hexafluoride type-a lipid microspheres
- Drug
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 8 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Appendicitis Acute
- Interventions
- Sulfur hexafluoride lipid-type A microspheres
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 8 Years to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Covid19, Multisystem Inflammatory Syndrome in Children (MIS-C)
- Interventions
- Sulfur hexafluoride lipid-type A microspheres
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Minute to 17 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Liver Neoplasms
- Interventions
- Sulfur Hexafluoride Lipid Microspheres, Contrast-Enhanced Ultrasound, Transarterial Chemoembolization, Medical Chart Review
- Drug · Procedure · Other
- Lead sponsor
- john eisenbrey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Trauma Abdomen
- Interventions
- Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON], contrast-enhanced ultrasound
- Drug · Device
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Vesico-Ureteral Reflux
- Interventions
- Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 6 Months to 35 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Diseases
- Interventions
- Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON], Lumason
- Drug
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- West Hills, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
- Conditions
- Coronary Artery Disease
- Interventions
- Lumason
- Drug
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • La Jolla, California • West Hills, California + 7 more
- Conditions
- Recurrent Renal Cell Carcinoma, Renal Cell Carcinoma
- Interventions
- Sulfur Hexafluoride Lipid Microspheres, Contrast-Enhanced Ultrasound, Computed Tomography, Magnetic Resonance Imaging, Electronic Health Record Review
- Drug · Procedure · Other
- Lead sponsor
- john eisenbrey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cirrhosis
- Interventions
- Contrast-Enhanced Ultrasound, Sulfur Hexafluoride Lipid Microspheres, Ultrasound
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
- Interventions
- Lumason, Sonazoid
- Diagnostic Test
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pulmonary Hypertension
- Interventions
- SonoVue, Placebo
- Drug
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Teaneck, New Jersey
- Conditions
- Kidney Cancer
- Interventions
- Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Lymphedema Arm
- Interventions
- Lumason, Optison, Definity
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Carcinoma
- Interventions
- Contrast-Enhanced Ultrasound, Perflutren Lipid Microspheres, Sulfur Hexafluoride Lipid Microspheres
- Procedure · Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Kidney Transplantation
- Interventions
- Lumason Contrast-Enhanced Ultrasound
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Hypoxic-Ischemic Encephalopathy, Brain Ischemia Hypoxia
- Interventions
- Sulfur hexafluoride lipid-type A microspheres
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Minute to 18 Months
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Tetralogy of Fallot, Pulmonary Insufficiency
- Interventions
- Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
- Drug
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 11 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- Hypertension, Portal
- Interventions
- SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles), SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Sinusoidal Obstruction Syndrome, Veno Occlusive Disease, Hepatic, Bone Marrow Transplant Complications, Stem Cell Transplant Complications
- Interventions
- Ultrasound Elastography, Contrast Enhanced Ultrasound (CEUS)
- Diagnostic Test · Drug
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 1 Month to 25 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri